Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Aziz Nazha, Hagop Kantarjian, Preetesh Jain, Carlos Romo, Elias Jabbour, Alfonso Quintas-Cardama, Raja Luthra, Lynne Abruzzo, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with tyrosine kinase inhibitors to determine their outcome based on their response at six months. Forty-four (10%) patients did not achieve major cytogenetic response at three months: 18 of 67 (27%) patients treated with imatinib 400; 18 of 196 (9%) with imatinib 800; and 8 of 193 (4%) with 2nd generation tyrosine kinase inhibitors. Among them, 19 (43%) achieved major cytogenetic response at six months and subsequently had an overall outcome similar to the patients who achieved a major cytogenetic response at three months. In conclusion, the response to tyrosine kinase inhibitors at three months is a static, one-time measure. Assessing the response at six months of patients with poor response at three months may provide a better predictor for longterm outcome.

Original languageEnglish (US)
Pages (from-to)1686-1688
Number of pages3
JournalHaematologica
Volume98
Issue number11
DOIs
StatePublished - Nov 1 2013

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months'. Together they form a unique fingerprint.

  • Cite this

    Nazha, A., Kantarjian, H., Jain, P., Romo, C., Jabbour, E., Quintas-Cardama, A., Luthra, R., Abruzzo, L., Borthakur, G., Ravandi, F., Pierce, S., O'Brien, S., & Cortes, J. (2013). Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica, 98(11), 1686-1688. https://doi.org/10.3324/haematol.2013.090282